Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities.
The molecular clock revisited: the rate of synonymous vs. replacement change in Drosophila.
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
View in:
PubMed
subject areas
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Bevacizumab
Clinical Protocols
Diabetic Retinopathy
Double-Blind Method
Female
Humans
Intravitreal Injections
Macular Edema
Male
Middle Aged
Randomized Controlled Trials as Topic
Ranibizumab
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins
Therapeutic Equivalency
Vascular Endothelial Growth Factor A
Visual Acuity
authors with profiles
Seenu Hariprasad